The company said the total investment will be Rs 40-50 lakh and it expects a revenue of Rs 100-150 crore in fiscal 2021with a decent profitability

A number of biologics with huge markets are going off-patent in the US. Do Indian pharmaceutical companies have it in them to play this high-cost, high-risk game of launching biosimilars?

Ogivri is the biosimilar version of Swiss drug maker Roches Herceptin, a breast cancer and gastric cancer drug with sales of $6.9 billion a year worldwide

Ogivri (Trastuzumab), jointly developed by Biocon and Mylan, is the biosimilar version of Swiss drug maker Roche's Herceptin.

Tata Motors has moved up from 104th position last year to 49th now and has also shown the largest increase in R&D (Research and Development) investments on the list.

Others in the top 10 list include IBM at the fourth place, followed by Unilever, Intel, McDonald's, Samsung, 3M and Hewlett-Packard, in that order.

Reliance Industries plans to invest Rs 1.5 lakh crore over three years, said Chairman Mukesh Ambani at the recent annual general meeting in Mumbai.

Is there a correlation between a company's research and development (R&D) expenditure and its innovation standing? The answer is clearly no, if one looks at Booz & Co's annual study on R&D spending, entitled 'The Global innovation 1000: Making Ideas Work'.

India Inc is waking up to nanotechnology, and this promises to change the way you live—whether by arresting the biological ageing process or curing diseases, such as cancer, diabetes and HIV-AIDS, or even bringing out the best from shampoos and airconditioners. A report by Nitya Varadarajan.